Targeting the Future of Pancreatic Cancer Care: RAS, Biomarkers, and Emerging Therapies

In this episode, Dr Paul E. Oberstein, Dr Andrew H. Ko, and Dr Efrat Dotan discuss recent advances in pancreatic cancer, including:

The evolving role of chemotherapy Utility of tumor treating fields for the treatment of locally advanced pancreatic adenocarcinoma Emerging RAS-targeted strategies and novel approaches for CLDN18.2- and MTAP-altered disease The potential impact of these developments on future treatment sequencing and supportive care 

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify.

Presenters:

Paul E. Oberstein, MD, MS
Section Chief, GI Oncology
Associate Professor of Medicine
Co-Director, KRAS Excellence Initiative
Perlmutter Cancer Center
NYU Langone Health
New York, New York

Andrew H. Ko, MD, FASCO
Professor of Medicine and Associate Chief
Division of Hematology/Oncology
University of California San Francisco
San Francisco, California

Efrat Dotan, MD, MTR
Clinical Professor of Medicine (Hematology/Oncology)
Executive Medical Director, Penn Medicine, Ann B. Barshinger Cancer Center
Penn Center for Cancer Care Innovation, Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Link to full program: 
https://bit.ly/44HPR1U

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.